Trial reportAmerican journal of ophthalmology2017
The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12.
Trial report in American journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of Topiramate Versus Acetazolamide in the Management of Idiopathic Intracranial Hypertension: ASystematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- The Relationship Between Optic Disc Volume, Area, and Frisén Score in Patients With Idiopathic Intracranial Hypertension.American journal of ophthalmology · 2018Trial
- Visual prognosis in idiopathic intracranial hypertension: observations from a retrospective cohort in Germany.Frontiers in neurology · 2025Article
- Visualization of Optic Nerve Structural Patterns in Papilledema Using Deep Learning Variational Autoencoders.Translational vision science & technology · 2024Article
- The manifestations of metabolic acidosis during acetazolamide treatment in a cohort of pediatric idiopathic intracranial hypertension.Pediatric nephrology (Berlin, Germany) · 2024Observational
- Perioperative Care of the Patient with Eye Pathologies Undergoing Nonocular Surgery.Anesthesiology · 2022Article
- Extent of transverse sinus stenosis does not predict visual outcomes in idiopathic intracranial hypertension.Eye (London, England) · 2022Article
- New Options (or not) for Treatment of Idiopathic Intracranial Hypertension.Current neurology and neuroscience reports · 2022Review
- Update on the Diagnosis and Treatment of Idiopathic Intracranial Hypertension.Seminars in neurology · 2019Review
- Acetazolamide Mitigates Intracranial Pressure Spikes Without Affecting Functional Outcome After Experimental Hemorrhagic Stroke.Translational stroke research · 2019Article
- Advances in the understanding of headache in idiopathic intracranial hypertension.Current opinion in neurology · 2019Review
- Idiopathic Intracranial Hypertension: The Monster Within.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo determine whether the beneficial effects of acetazolamide (ACZ) in improving vision at 6 months continues to month 12 in participants of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).
designNonrandomized clinical study.
methodsIn the IIHTT, subjects were randomly assigned to placebo-plus-diet or maximally tolerated dosage of acetazolamide-plus-diet. At 6 months subjects transitioned from study drug to ACZ. This resulted in the following groups: (1) ACZ to ACZ; n = 34; (2) placebo to ACZ; n = 35; (3) ACZ to no treatment; n = 16; and (4) placebo to no treatment; n = 11. Ninety-six IIHTT subjects had evaluations at 6 and 12 months. Our main outcome measure was change from month 6 to month 12 in visual field mean deviation (MD) with secondary measures being change in papilledema grade, ETDRS scores, and quality-of-life (QoL) measures.
resultsThe ACZ to ACZ group improved 0.35 dB, P = .05; placebo subjects with no ACZ improved 0.81 dB MD, P = .07 at 12 months. The other groups improved 0.35-0.46 dB MD. Mean improvements in papilledema grade occurred most markedly in the group that exchanged placebo for ACZ (0.91 units, P < .001). QoL and headache disability scores showed significant improvements in the placebo group with added ACZ.
conclusionImprovements in MD continued from month 6 to month 12 of the IIHTT in all treatment groups, most marked in the placebo group tapered off study drug. Adding ACZ to the placebo group significantly improved papilledema grade, headache, and QoL measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.